ArticleMycoses2021
Accuracy of galactomannan testing on tracheal aspirates in COVID-19-associated pulmonary aspergillosis.
Article in Mycoses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Guideline
- Antifungal therapy in the management of fungal secondary infections in COVID-19 patients: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Incidence and mortality of COVID-19-associated pulmonary aspergillosis: A systematic review and meta-analysis.Mycoses · 2021Pooled it
- Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review.The Journal of hospital infection · 2021Pooled it
- [S1 guideline: diagnosis and treatment of invasive pulmonary aspergillosis in critically ill/intensive care patients].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2025Review
- Diagnostic accuracy of galactomannan and lateral flow assay in invasive aspergillosis: A diagnostic meta-analysis.Heliyon · 2024Article
- COVID-19-associated pulmonary aspergillosis in intensive care unit: A real-life experience.Heliyon · 2024Article
- A prediction model for secondary invasive fungal infection among severe SARS-CoV-2 positive patients in ICU.Frontiers in cellular and infection microbiology · 2024Article
- Outcomes of Patients with COVID-19 and Fungal Coinfections: A Systematic Review and Meta-Analysis Study.Iranian journal of pathology · 2024Review
- Diagnostic performance and longitudinal analysis of fungal biomarkers in COVID-19 associated pulmonary aspergillosis.Heliyon · 2023Article
- Review
- The SSS revolution in fungal diagnostics: speed, simplicity and sensitivity.British medical bulletin · 2023Article
- Microbiological Non-Culture-Based Methods for Diagnosing Invasive Pulmonary Aspergillosis in ICU Patients.Diagnostics (Basel, Switzerland) · 2023Review
- Comparison of Multi-locus Genotypes Detected inJournal of fungi (Basel, Switzerland) · 2023Article
- Impact of coronavirus disease 2019 (COVID-19) pandemic in hospital-acquired infections and bacterial resistance at an oncology hospital.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2023Article
- Review
- "CAPA in Progress": A New Real-Life Approach for the Management of Critically Ill COVID-19 Patients.Biomedicines · 2022Article
- Article
- Invasive Respiratory Fungal Infections in COVID-19 Critically Ill Patients.Journal of fungi (Basel, Switzerland) · 2022Review
- Prevalence of COVID-19-Associated Pulmonary Aspergillosis: Critical Review and Conclusions.Journal of fungi (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOur aim was to evaluate the performance of two galactomannan (GM) assays (Platelia Aspergillus EIA, Bio-Rad
methodsWe included critically ill patients, performed GM-EIA and GM-Lateral Flow Assay (GM-LFA) in TA and followed them until development of COVID-19-associated pulmonary aspergillosis (CAPA) or alternate diagnosis. CAPA was defined according to the modified AspICU criteria in patients with SARS-CoV-2 infection. We estimated sensitivity, specificity, positive and negative predictive values for GM-EIA, GM-LFA, the combination of both or either positive results for GM-EIA and GM-LFA. We explored accuracy using different breakpoints, through ROC analysis and Youden index to identify the optimal cut-offs. We described antifungal treatment and 30-day mortality.
resultsWe identified 14/144 (9.7%) patients with CAPA, mean age was 50.35 (SD 11.9), the median time from admission to CAPA was 8 days; 28.5% received tocilizumab and 30-day mortality was 57%. ROC analysis and Youden index identified 2.0 OD as the best cut-off, resulting in sensitivity and specificity of 57.1% and 81.5% for GM-EIA and 60% and 72.6% for GM-LFA, respectively.
conclusionsThe diagnostic performance of GM in tracheal aspirates improved after using a cut-off of 2 OD. Although bronchoalveolar lavage testing is the ideal test, centres with limited access to bronchoscopy may consider this approach to identify or rule out CAPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.